AccuType® Warfarin

The AccuType® Warfarin test contains 1 test with 1 biomarker.

Warfarin (Coumadin®) therapy is associated with significant complications because of its narrow therapeutic index and large interpatient dosage variation necessary to achieve an optimal therapeutic response. This variation is due to both genetic and environmental factors. A promoter variant (-1639 G?A) of the Vitamin K epoxide complex subunit 1 (VCR) accounts for 25%-44% of this variability and variants of the cytochrome P enzyme C (SPCA) account for 10%-15% of this variability. Identification of these warfarin sensitive variants of the VKORC1 and the CYP2C9 genes may allow a more individualized therapy and reduced risk of bleeding complications.

The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.

Also known as: 2C9, AccuType Warfarin, CYP2C9, CYP2C9 Genotype, Vitamin K Epoxide Reductase Complex, VKORC1, VKORC1 Genotype, Warfarin Sensitivity Genotyping

Accutype(R) Warfarin